Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093051 | 1.00 | KMT2A (0.50) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL29400732 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL29400312 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL12898821 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL178688 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL119653 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL119648 | 0.90 | KMT2A (0.55) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL13938802 | 0.89 | KMT2A (0.59) | KMT2ATLR2MDM2 | |
| SCHEMBL14123951 | 0.88 | KMT2A (0.53) | KMT2ATLR2MDM2CASP3CASP1 | |
| SCHEMBL30972259 | 0.87 | KMT2A (0.48) | KMT2ATLR2MDM2CASP3CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044693-A1 | Levetiracetam Immunoassays | ARK DIAGNOSTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20120190047-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2012-07-26 | — | — | US | disclosed |
| US-8168756-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190047-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | KMT2A 1674/4885TLR2 4281/4885MDM2 3125/4885 |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | GABRG1, GABRA6, LY96 | KMT2A 1674/4885TLR2 4281/4885MDM2 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.